LivaNova Reports Third-Quarter 2023 Results

About this update from Livanova Plc

[{"type":"text","content":" LONDON--(BUSINESS WIRE)--\nLivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the quarter ended September 30, 2023 and raised full-year 2023 revenue and adjusted diluted earnings per share guidance.\n\n\nFinancial Summary and Highlights1\n\n\n\nThird-quarter revenue of $286.1 million increased 13.3% on a reported basis and increased 12.1% on a constant-currency basis, as compared to the prior-year period\n\n\n\nThird-quarter U.S. GAAP diluted loss per share was $0.14 and adjusted diluted earnings per share was $0.73\n\n\n\nReceived U.S. FDA 510(k) clearance and CE Mark for its EssenzTM In-Line Blood Monitor\n\n\n\n“LivaNova delivered double-digit revenue growth across all regions, improved profitability and achieved important clearances for the Essenz In-Line Blood Monitor in the third quarter,” said Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova. \"Our performance reflects strong execution throughout the organization as demonstrated in all three Business Units. We look forward to building on these results with a firm focus on patients and performance in the fourth quarter and in 2024.\"\n\n\nThird-Quarter 2023 Results\n\n\nThe following table summarizes revenue for the third quarter of 2023 by segment (in millions):\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\nThree Months Ended\n\n\n\n\nSeptember 30,\n\n\n\n\n\n\n \n\n\n\n\n\n\n% Change\n\n\n\n\n\n\n \n\n\n\n\n\n\nConstant-Currency\n\n\n\n\n% Change2\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2023\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n2022\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nCardiopulmonary\n\n\n\n\n\n\n \n\n\n\n\n\n\n$144.8\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n$121.0\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n19.7\n\n\n\n\n\n\n%\n\n\n\n\n\n\n \n\n\n\n\n\n\n18.1\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNeuromodulation\n\n\n\n\n\n\n \n\n\n\n\n\n\n128.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n121.8\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n5.8\n\n\n\n\n\n\n%\n\n\n\n\n\n\n \n\n\n\n\n\n\n5.2\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nAdvanced Circulatory Support\n\n\n\n\n\n\n \n\n\n\n\n\n\n11.0\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n8.6\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n26.8\n\n\n\n\n\n\n%\n\n\n\n\n\n\n \n\n\n\n\n\n\n26.6\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nOther\n\n\n\n\n\n\n \n\n\n\n\n\n\n1.5\n\n\n\n\n\...

More updates from Livanova Plc